NCT07630298 A Comparative Study of Driving Performance Among Adolescents With Autism Spectrum Disorder and Neurotypical Adolescents
| NCT ID | NCT07630298 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hopital La Musse |
| Condition | Autism Spectrum Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 22 participants |
| Start Date | 2026-10-05 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 22 participants in total. It began in 2026-10-05 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to compare the number of driving errors made by novice adolescents (0-5 hours of driving instruction) with ASD to those made by neurotypical adolescents during a standardized driving simulator assessment. The secondary objectives of the study are to: * Compare the visual strategies used by adolescents with ASD to those of neurotypical adolescents during a driving assessment on a simulator. * Compare the types of errors and driving performance (i.e., speed, reaction time, following distance, and braking distance) of adolescents with ASD to those of neurotypical adolescents during the driving simulator assessment. * Compare the driving performance of these two groups during a real-world road assessment using the TRIP scale. * Examine the consistency between driving performance measured in the simulator and that observed in real-world conditions for both groups. * Compare the anxiety levels of these two groups during driving tests on the simulator and on the road.
Eligibility Criteria
Inclusion Criteria: ASD Group * Adolescents aged 15 to 17, * With a confirmed diagnosis of ASD by a physician, * Without an intellectual disability, with a Fluid Reasoning Index (IRF) greater than 80, * Who have passed the written driver's license exam, * With no or very limited driving experience (\<5 hours), * Enrolled in the social security system. Neurotypical group: * Adolescents aged 15 to 17, * Without a diagnosis of neurodevelopmental disorders or learning disabilities, * With a standard educational background, * Who have passed the written driver's license exam, * With no or very limited driving experience (\<5 hours), * Enrolled in the social security system. Exclusion Criteria: * Adolescents with ADHD (attention-deficit/hyperactivity disorder) and/or ODD (oppositional defiant disorder) and/or IDD (intellectual disability) and/or SLI (specific language impairment) with associated comprehension difficulties, * Adolescents who already have a driver's license, * Adolescents currently taking driving lessons and/or with more than 5 hours of driving experience, * Adolescents who have suffered a head injury during childhood, * Other serious medical conditions that may interfere with participation in the sessions, * Participation in another research protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07630298 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 17 Years, studying Autism Spectrum Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07630298 currently recruiting?
Yes, NCT07630298 is actively recruiting participants. Contact the research team at h.baillet@hlrs-lamusse.net for enrollment information.
Where is the NCT07630298 trial being conducted?
This trial is being conducted at Saint-Sébastien-de-Morsent, France.
Who is sponsoring the NCT07630298 clinical trial?
NCT07630298 is sponsored by Hopital La Musse. The trial plans to enroll 22 participants.